Literature DB >> 19156422

Hemolytic uremic syndrome with ischemic glomerulonephropathy and obliterative vasculopathy in a systemic sclerosis patient treated with cyclosporine-A.

Wei-Sheng Chen1, An-Hang Young, Hon-Pin Wang, De-Feng Huang.   

Abstract

Hemolytic uremic syndrome (HUS) is not a commonly reported complication in post-transplantation patients treated with cyclosporine-A (CSA), and is extremely rare in systemic sclerosis (SSc) patients treated with this drug. CSA may contribute to the development of chronic ischemic glomerulonephropathy and vasculopathy, features not easily distinguished from SSc-related nephropathy. Here, we describe a 41-year-old Chinese man with diffuse-type SSc treated with CSA who developed thrombocytopenia, acute renal failure and hemolytic anemia and was diagnosed with HUS. Renal function and thrombocytopenia improved gradually after intensive treatment of plasma exchange (PE) and high-dose steroid therapy. After PE, renal biopsy showed ischemic glomerulonephropathy and obliterative vasculopathy. This case illustrates that PE can improve the hematological disorders and characteristic renal changes of HUS in SSc patients treated with CSA. However, this therapy may not be effective in normalizing serum creatinine level in SSc patients once CSA has triggered the normal kidney to develop glomerulonephropathy and vasculopathy with ischemic and sclerotic changes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19156422     DOI: 10.1007/s00296-008-0826-y

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  10 in total

1.  Long-term treatment of patients affected by systemic sclerosis with cyclosporin A.

Authors:  G Filaci; M Cutolo; M Basso; G Murdaca; L Derchi; R Gianrossi; F Ropolo; P Zentilin; A Sulli; F Puppo; F Indiveri
Journal:  Rheumatology (Oxford)       Date:  2001-12       Impact factor: 7.580

Review 2.  Cyclosporine.

Authors:  B D Kahan
Journal:  N Engl J Med       Date:  1989-12-21       Impact factor: 91.245

3.  Cellular mechanisms of vascular injury mediated by calcineurin inhibitors.

Authors:  Santiago Lamas
Journal:  Kidney Int       Date:  2005-08       Impact factor: 10.612

4.  Progressive systemic sclerosis and renal transplantation: a contraindication to ciclosporin.

Authors:  J C Ruiz; F Val; A L de Francisco; E de Bonis; J A Zubimendi; M Prieto; E Canga; M Arias
Journal:  Nephron       Date:  1991       Impact factor: 2.847

5.  Endothelial and fibroblastic activation in scleroderma. The myth of the "uninvolved skin".

Authors:  H N Claman; R C Giorno; J R Seibold
Journal:  Arthritis Rheum       Date:  1991-12

Review 6.  Thrombotic thrombocytopenic purpura in the setting of systemic sclerosis.

Authors:  Augustine M Manadan; Charlotte Harris; Joel A Block
Journal:  Semin Arthritis Rheum       Date:  2005-02       Impact factor: 5.532

7.  Hemolytic uremic syndrome in a patient with systemic sclerosis treated with cyclosporin A.

Authors:  H Zachariae; H E Hansen; T S Olsen
Journal:  Acta Derm Venereol       Date:  1992-08       Impact factor: 4.437

8.  Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients.

Authors:  T Bertani; P Ferrazzi; A Schieppati; P Ruggenenti; A Gamba; L Parenzan; G Mecca; N Perico; O Imberti; A Remuzzi
Journal:  Kidney Int       Date:  1991-08       Impact factor: 10.612

9.  High-dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome.

Authors:  Paul Coppo; Annette Bussel; Sabine Charrier; Christophe Adrie; Lionel Galicier; Emmanuelle Boulanger; Agnès Veyradier; Thierry Leblanc; Corinne Alberti; Elie Azoulay; Jean-Roger Le Gall; Benoît Schlemmer
Journal:  Medicine (Baltimore)       Date:  2003-01       Impact factor: 1.889

10.  Nephrotoxicity of cyclosporin A after allogeneic marrow transplantation: glomerular thromboses and tubular injury.

Authors:  H Shulman; G Striker; H J Deeg; M Kennedy; R Storb; E D Thomas
Journal:  N Engl J Med       Date:  1981-12-03       Impact factor: 91.245

  10 in total
  3 in total

Review 1.  A case report of a psoriatic arthritis patient on hemodialysis treated with tumor necrosis factor blocking agent and a literature review.

Authors:  Ioanna Saougou; Charalampos Papagoras; Theodora E Markatseli; Paraskevi V Voulgari; Alexandros A Drosos
Journal:  Clin Rheumatol       Date:  2010-05-21       Impact factor: 2.980

Review 2.  Calcineurin inhibitors in systemic sclerosis - a systematic literature review.

Authors:  Nina N Hofmann; Robert A Ambühl; Suzana Jordan; Oliver Distler
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-05-19       Impact factor: 3.625

Review 3.  Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab.

Authors:  Arif Asif; Ali Nayer; Christian S Haas
Journal:  J Nephrol       Date:  2016-11-15       Impact factor: 3.902

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.